1.1.1. The global pharmaceutical industry plays a crucial role in advancing human health and well-being. Beyond the development of lifesaving and life-enhancing medical treatments, the sector is a significant driver of economic growth worldwide. Its continuous cycle of innovation not only addresses existing diseases but also responds to emerging health threats, reinforcing its role as a key pillar of global healthcare and economic stability.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
1.2.1. Despite the industry’s overall expansion, investment returns have underperformed. The PwC Pharma Index delivered a 7.6% return to shareholders from 2018 through November 2024, significantly lagging behind the 15% return of the S&P 500 over the same period.[5] The situation worsened in 2024, with the PwC Pharma Index returning 13.9%, while the S&P 500 surged by 28.7%. Investor sentiment remains cautious, influenced by persistent high interest rates and ongoing economic uncertainty.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
1.3.1. The industry is also facing a wave of major patent expirations, peaking in 2027–2028, when a total of $100 billion in annual sales — equivalent to 6.6% of global pharma revenues — will be at risk due to loss of exclusivity (LOE).[2] Among the most high-profile drugs set to lose patent protection during this period are Keytruda, Opdivo, Eliquis, Ibrance, and Trulicity, which collectively generated $58 billion in sales in 2023. By 2030, sales of these drugs are expected to decline by more than 50% due to biosimilar and generic competition.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
1.4.1. While emerging therapeutic modalities are unlikely to break into the top 10 best-selling drugs by 2030, they are gaining significant traction due to their ability to target novel disease mechanisms. Leading this wave of innovation are:
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
1.5.1. The increasing adoption of these next-generation technologies is contributing to a fundamental market shift — bringing the industry closer to a 50/50 balance between small molecules and biologics.[2] This evolution underscores the growing emphasis on complex, high-value therapies that provide more targeted and durable treatment effects.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
1.6.1. Small molecule active pharmaceutical ingredients (APIs) hold paramount significance within the global pharmaceutical industry. Despite the attention given to biologics and other advanced therapies, small molecules have historically comprised the largest portion of pharmaceuticals and represent 69% of all new drug approvals (NDAs) since 2013 (Figure 1).[8] The trend continues through 2024. Two-thirds of 2024 NDAs were for small molecules (Figure 2).[8]
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
Pills for Medication
1.7.1. The formation of pills for medical dosing dates back to 1500 BCE in Egypt, where they were probably developed for the same reasons they are still used today: their easy, reliable delivery of medication to a patient. The early pills may have been coated with honey or grease to create a crude film that would make swallowing easier. Early trademarks were stamped into pills as far back as 500 BCE, when ancient Romans mass-produced pills in equipment that compressed the medication into regular shapes.[9]
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.